Abstract:O177* Purpose: It is established that transplant tolerance can be adoptively transferred from tolerant recipients to a naive recipient by T cells, a phenomena termed ,,infectious tolerance“. To date, the ability of other cells to transfer tolerance has not been demonstrated. The present study aims to determine whether tolerogenic dendritic cells (Tol-DC) isolated from tolerant mice can transfer graft-specific tolerance to naive recipients, and to dissect the mechanisms underlining infectious tolerance induced by Tol-DC. Methods: BALB/c mice receiving C57BL/6 cardiac allografts were treated with LF 15-0195, a novel analogue of 15-deoxyspergualine at a dose of 2 mg/kg for 20 days. Long-term survivors (>100 days) were defined as tolerant recipients. Tol-DC were isolated from tolerant recipients by anti-CD11c mAb-conjugated MACS beads. Tol-DC were intravenously injected into syngeneic (BALB/c) recipients followed by allogeneic (C57/BL6>Balb/c) heterotopic heart transplantation. Results: The Tol-DC isolated from tolerant recipients demonstrated an immature phenotype as exemplified by diminished expression of MHC II, CD40, and CD86. Functionally, Tol-DC failed to stimulate allogeneic T cell responses in MLR. Furthermore, the addition of Tol-DC isolated from tolerant recipients inhibited ongoing MLR, suggesting Tol-DC play a regulatory role. To further investigate the in vivo regulatory function of Tol-DC, ex vivo isolated Tol-DC (5x106 cells/mouse) from tolerant recipients were adoptively transferred into naive syngeneic recipients. While transferring control DC resulted no protection of allografts (MST 13 ± 1 day), transferring Tol-DC significantly prolonged allograft survival (MST 45 ± 8 days) in the absence of immune suppressants, suggesting an “infectious tolerance” occurred after adoptive transfer of Tol-DC. We next investigated whether transfer of Tol-DC was associated with generation of Treg. Indeed, subsequent to Tol-DC adoptive transfer, an increase in the CD4+CD25+ Treg subset was observed. Furthermore, CD4+CD25+CTLA4+ cells were detected at 31% after Tol-DC transfer compared to 6.1% in controls. Functionally, these Treg inhibited ongoing MLR in vitro. Finally, we examined the expression of indolamine-2,3-deoxygenase (IDO), an novel DC-derived T cell inhibiting enzyme, was remarkably up-regulated in the spleens of recipients after adoptive transfer of Tol-DC but not control DC. Conclusions: This study is the first demonstration of infectious tolerance by DC. The transplant tolerance can be adoptively transferred from a tolerant recipients to a naïve mouse. Mechanisms involved include generation of Treg in vivo and upregulation of IDO.

Bispecific antibodies tethering innate receptors induce human tolerant dendritic cells and regulatory T cells

A novel bispecific antihuman CD40/CD86 fusion protein with t-cell tolerizing potential

Synergistic Tolerance Induced by LF15-0195 and Anti-Cd45rb Monoclonal Antibody Through Suppressive Dendritic Cells1

Targeting DEC-205-DCIR2+ dendritic cells promotes immunological tolerance in proteolipid protein-induced experimental autoimmune encephalomyelitis

A Native-Like Bispecific Antibody Suppresses the Inflammatory Cytokine Response by Simultaneously Neutralizing Tumor Necrosis Factor-Alpha and Interleukin-17A

A Role for Anti-Cd45rb Monoclonal Antibody Treatment Upon Dendritic Cells.

Tolerogenic dendritic cells generated in vitro using a novel protocol mimicking mucosal tolerance mechanisms represent a potential therapeutic cell platform for induction of immune tolerance

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

Therapeutic Control of B Cell Activation Via Recruitment of Fc Gamma Receptor Iib (cd32b) Inhibitory Function with A Novel Bispecific Antibody Scaffold

Targeting dendritic cells with a PD-L1 based bispecific antibody rejuvenates specific anti-tumor T cells

Targeting T cells with tetravalent bispecific antibodies for the treatment of graft versus host disease

Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.

Antibody-induced transplantation tolerance that is dependent on thymus-derived regulatory T cells.

Dendritic Cell Vaccine Design: Strategies for Eliciting Peripheral Tolerance as Therapy of Autoimmune Diseases

Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting

Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators

INFECTIOUS TOLERANCE MEDIATED BY DENDRITIC CELLS: A NOVEL MECHANISM OF ALLOGRAFT ACCEPTANCE THROUGH ACTIVATION OF T REGULATORY CELLS

Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1

SYNERGISTIC TOLERANCE BY ADOPTIVE TRANSFER OF TOLEROGENIC DENDRITIC CELLS AND T REGULATORY CELLS:

Anti-CD(45)RB Monoclonal Antibody Induces Immunologic Toleration by Suppressing Dendritic Cells.

Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date